{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:00:48Z","timestamp":1790352048956,"version":"4.1.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic actinic dermatitis (CAD) is a rare immune-mediated photodermatosis that may be severe, generalized and refractory to conventional therapies. We describe four men (aged 44\u201365\u2005years) with long-standing severe CAD, which was unresponsive to multiple systemic treatments, including immunosuppressants, dupilumab and tofacitinib. All patients presented with marked photosensitivity and two had erythroderma. Extensive investigation excluded cutaneous T-cell lymphoma. Photobiological testing demonstrated reduced minimal erythema doses to ultraviolet B adjusted for phototype, supporting the diagnosis of CAD. Upadacitinib (15\u201330\u2005mg once daily) was initiated off-label. Clinical improvement occurred within 4 weeks, with complete remission achieved between 4 and 8 weeks in all patients. Remission was sustained for up to 12\u2005months of follow-up. Treatment was well tolerated, with only mild acneiform eruption and transient hypertriglyceridaemia in one patient. These findings suggest that selective Janus kinase 1 inhibition may represent a therapeutic option in severe treatment-refractory CAD.<\/jats:p>","DOI":"10.1093\/ced\/llag160","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:42:45Z","timestamp":1775734965000},"page":"1881-1886","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of severe refractory chronic actinic\u00a0dermatitis with upadacitinib: a case series of four\u00a0patients"],"prefix":"10.1093","volume":"51","author":[{"given":"Nidia","family":"Planella-Fontanillas","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Medicine and Life Sciences Department, Pompeu Fabr University , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Magdaleno-Tapial","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Exp\u00f3sito-Serrano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Parc Taul\u00ed University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ferran-Farr\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Medicine and Life Sciences Department, Pompeu Fabr University , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"P\u00e9rez Ferriols","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Mohammad Porras","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Medicine and Life Sciences Department, Pompeu Fabr University , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M","family":"Gim\u00e9nez-Arnau","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Medicine and Life Sciences Department, Pompeu Fabr University , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Medicine and Life Sciences Department, Pompeu Fabr University , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-6055","authenticated-orcid":false,"given":"Ramon M","family":"Pujol","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Medicine and Life Sciences Department, Pompeu Fabr University , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"2026092511024344100_llag160-B1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/DER.0000000000000531","article-title":"Chronic actinic dermatitis revisited","volume":"31","author":"Wang","year":"2020","journal-title":"Dermatitis"},{"key":"2026092511024344100_llag160-B2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/DAD.0000000000000076","article-title":"Chronic actinic dermatitis\/actinic reticuloid: a clinicopathologic and immunohistochemical analysis of 37 cases","volume":"36","author":"Sidiropoulos","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"2026092511024344100_llag160-B3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.det.2014.03.007","article-title":"Chronic actinic dermatitis","volume":"32","author":"Paek","year":"2014","journal-title":"Dermatol Clin"},{"key":"2026092511024344100_llag160-B4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/ced\/llaf487","article-title":"Efficacy of monoclonal antibodies and JAK inhibitors in the treatment of idiopathic photosensitive skin disorders: a systematic review","volume":"51","author":"Alawadhi","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026092511024344100_llag160-B5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/11315930-000000000-00000","article-title":"Diagnosis and pharmacological treatment of chronic actinic dermatitis in the elderly: an update","volume":"27","author":"Forsyth","year":"2010","journal-title":"Drugs Aging"},{"key":"2026092511024344100_llag160-B6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/ajd.14293","article-title":"Dupilumab for chronic actinic dermatitis: a case series and review of the literature","volume":"65","author":"Holmes","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026092511024344100_llag160-B7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/bjd\/ljae180","article-title":"Dupilumab in chronic actinic dermatitis: a retrospective case series","volume":"191","author":"O\u2019Reilly","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026092511024344100_llag160-B8","doi-asserted-by":"crossref","first-page":"e9590","DOI":"10.1002\/ccr3.9590","article-title":"Dupilumab-induced erythrodermic psoriasiform dermatitis in chronic actinic dermatitis: case report and innovative treatment approach","volume":"12","author":"Khodeir","year":"2024","journal-title":"Clin Case Rep"},{"key":"2026092511024344100_llag160-B9","doi-asserted-by":"crossref","first-page":"104344","DOI":"10.1016\/j.drudis.2025.104344","article-title":"JAK inhibitors as a promising therapy for immune-mediated photodermatoses","volume":"30","author":"Malekan","year":"2025","journal-title":"Drug Discov Today"},{"key":"2026092511024344100_llag160-B10","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1002\/ski2.243","article-title":"Remission of chronic actinic dermatitis on baricitinib: a case report","volume":"3","author":"Maguire","year":"2023","journal-title":"Skin Health Dis"},{"key":"2026092511024344100_llag160-B11","doi-asserted-by":"crossref","first-page":"1598972","DOI":"10.3389\/fphar.2025.1598972","article-title":"Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag160\/68039642\/llag160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1881\/68039642\/llag160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1881\/68039642\/llag160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:02:57Z","timestamp":1790348577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/10\/1881\/8652477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,11]]},"published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag160","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,11]]}}}